Advanced Biomed Inc. Reports Turnaround with $5.98M Net Income for Nine-Month Period Ending March 31, 2026

Advanced Biomed Inc. reported its financial results for the nine-month period ending March 31, 2026, revealing a significant turnaround in profitability compared to the previous fiscal year. The company recorded a net income of $5.98 million, a stark contrast to a net loss of $2.56 million during the same period in 2025. This improvement was primarily driven by a one-time gain of $7.35 million from the disposal of its subsidiary, Advanced Biomed (HK) Limited, which was completed in December 2025. The company’s total revenue for the nine-month period was not specified, as it has not yet generated revenue from product sales.

In terms of operational expenses, Advanced Biomed reported total operating expenses of $1.31 million for the nine-month period, up from $1.08 million in the prior year. Research and development expenses increased by 11% to $665,140, reflecting ongoing investments in clinical development activities. General and administrative expenses rose by 36% to $646,213, largely due to increased professional fees and staff costs. The company also reported a net cash outflow of $1.36 million from operating activities, although this was an improvement from the $4.28 million outflow recorded in the previous year.

The company’s balance sheet showed total current assets of $10.53 million as of March 31, 2026, down from $13.24 million at the end of the previous fiscal year. Current liabilities significantly decreased to $1.43 million from $10.09 million, primarily due to the deconsolidation of the disposed subsidiary. This resulted in a working capital surplus of $9.10 million, compared to $3.14 million in the prior year. The company’s cash position at the end of the reporting period was $2.60 million, a decrease from $2.87 million as of June 30, 2025.

Strategically, Advanced Biomed has made significant organizational changes, including the acquisition of Acellent Technologies (Hong Kong) Co. Limited, which was finalized on April 27, 2026. This acquisition is part of the company's pivot towards AI-powered financial audit solutions. Additionally, the company has implemented a 1-for-20 reverse stock split to maintain compliance with Nasdaq listing requirements. As of March 31, 2026, the company had 1,382,133 shares of common stock outstanding, reflecting the impact of the reverse split.

Looking ahead, Advanced Biomed faces challenges in achieving sustainable revenue generation, as it has not yet launched any products commercially. The company anticipates continued losses in the near term as it focuses on regulatory approvals and product development. Management has indicated that it may seek additional capital to support its operations and has entered into a short-term loan agreement to bolster liquidity. The company remains committed to its research and development efforts, particularly in the oncology sector, while navigating the complexities of regulatory compliance and market entry.